Wall Street sees multi-billion dollar debut for Lilly's obesity pill despite Novo lead
Wall Street sees multi-billion dollar debut for Lilly's obesity pill despite Novo lead
BTC
ETH
USDT
XRP
USDC
SOL
TRX
FIGR_HELOC
DOGE
WBT
USDS
HYPE
LEO
ADA
BTC
ETH
USDT
XRP
USDC
SOL
TRX
FIGR_HELOC
DOGE
WBT
USDS
HYPE
LEO
ADA
BTC
ETH
USDT
XRP
USDC
SOL
TRX
FIGR_HELOC
DOGE
WBT
USDS
HYPE
LEO
ADA
BTC
ETH
USDT
XRP
USDC
SOL
TRX
FIGR_HELOC
DOGE
WBT
USDS
HYPE
LEO
ADA
Here's what a handful of investing professionals say about the market's rapid recovery - and the fragile Middle East truce.
Most popular articles this week
Latest news from global stock markets, tech giants, and financial sectors
Browse ArticlesBitcoin, Ethereum, altcoins, DeFi, NFTs, and blockchain technology
Browse ArticlesGold, silver, oil, natural gas, and other precious commodities
Browse Articles
Wall Street sees multi-billion dollar debut for Lilly's obesity pill despite Novo lead
Hims & Hers shares jumped nearly 50% in premarket trade on Monday after a report it has ended a dispute with Novo Nordisk by striking a partnership with th...
Novo Nordisk's study showing a new drug wasn't as good as a rival's led one sell-side analyst to downgrade the stock for the first time in five years.
UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo NordiskIn a pl...
Novo Nordisk slump wipes out last Wegovy-era gains after trial setback
Stock Market Today: The Dow Jones index dropped Monday on higher Trump tariffs. Novo stock plunged on weight-loss drug trial results.
Novo Nordisk shares were under pressure on Monday as the struggling Danish pharmaceutical said a head-to-head study found a drug in development didn't cut...
Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial
Novo Nordisk shares plunge after obesity drug falls short of rival in trial
CagriSema achieved 23% weight loss after 84 weeks of treatmentCagriSema 2.4/2.4 mg did not meet the primary endpoint of showing non-inferiority on weight l...
Novocure shares surge after FDA approves pancreatic cancer device
Hims & Hers stock tumbled in early action on Monday after the U.S. company quickly reversed plans to introduce its own version of Novo Nordisk's Wegovy ora...